In HIV-infected patients with abdominal obesity and elevated baseline ALT or AST, visceral fat responders to tesamorelin had greater ALT reductions than non-responders over 26 weeks.
In plain wordsIn people with HIV and extra belly fat, tesamorelin responders had a larger ALT liver enzyme drop than non-responders.
- Peptide
- Tesamorelin
- Outcome
- DecreaseALT change at 26 weeks in VAT responders
- Study
n: not reported in source
- Comparator
- VAT non-responders given tesamorelin
- Analysis
- Exploratory
- Outcome group
- Liver fat and liver function · Liver
- Studied dose
- Dose not stated · 26 weeksAs given in this study (human).
Measurements
- ALT change, responders
- −8.9 U/l
- 26 weeks
- ALT change, non-responders
- 1.4 U/l
- 26 weeks
Source sentences
In study participants assigned to tesamorelin with baseline ALT or AST more than 30 U/l, VAT responders experienced greater reductions in ALT (-8.9 ± 22.6 vs. 1.4 ± 34.7 U/l, P = 0.004) and AST (-3.8 ± 12.9 vs. 0.4 ± 22.4 U/l, P = 0.04) compared with nonresponders over 26 weeks.
2 context sentences(design, population, supporting numbers)
We utilized data from two multicenter Phase III trials of tesamorelin among 806 HIV-infected patients with abdominal obesity.
Within this group, we compared changes in ALT and AST in VAT responders vs. nonresponders after 26 weeks of treatment, and then assessed the effects of drug discontinuation on these endpoints over a subsequent 26-week period.